Literature DB >> 21327049

Regulation of the earliest immune response to in utero hematopoietic cellular transplantation.

Amir M Alhajjat1, Emily T Durkin, Aimen F Shaaban.   

Abstract

In Utero Hematopoietic Cellular Transplantation (IUHCT) is a promising intervention to treat a wide range of congenital disease. Through the presentation of donor cells to the immature immune system, mixed hematopoietic chimerism and donor-specific tolerance can be achieved. However, the failure of engraftment in prenatal recipients in which no immunodeficiency exists suggests the existence of a fetal immune barrier to transplantation. Although the possible barriers include effectors of the adaptive and innate immune system, our recent findings and ongoing investigations indicate that the barrier most likely resides in the developing NK cells. A chimerism level above a certain threshold during NK cell development is necessary to overcome rejection. Clinically, this transplantation barrier might also exist in early human fetal NK cells. Understanding the fetal immune barrier to allotransplantation is essential in advancing clinical application of IUHCT. Herein, we provide a short summary and new evidence for the earliest immune response to prenatal transplantation.

Entities:  

Year:  2010        PMID: 21327049      PMCID: PMC3023625          DOI: 10.4161/chim.1.2.13147

Source DB:  PubMed          Journal:  Chimerism        ISSN: 1938-1964


  15 in total

1.  Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC.

Authors:  C Roth; J R Carlyle; H Takizawa; D H Raulet
Journal:  Immunity       Date:  2000-07       Impact factor: 31.745

Review 2.  In utero hematopoietic stem cell transplantation: progress toward clinical application.

Authors:  Demetri Merianos; Todd Heaton; Alan W Flake
Journal:  Biol Blood Marrow Transplant       Date:  2008-04-25       Impact factor: 5.742

3.  MHC class I expression protects target cells from lysis by Ly49-deficient fetal NK cells.

Authors:  J A Toomey; S Shrestha; S A de la Rue; F Gays; J H Robinson; Z M Chrzanowska-Lightowlers; C G Brooks
Journal:  Eur J Immunol       Date:  1998-01       Impact factor: 5.532

4.  Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells.

Authors:  Bartosz Grzywacz; Nandini Kataria; Magdalena Sikora; Robert A Oostendorp; Elaine A Dzierzak; Bruce R Blazar; Jeffrey S Miller; Michael R Verneris
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

5.  Phenotypic and functional characterization of long-lived NK cell lines of different maturational status obtained from mouse fetal liver.

Authors:  M Manoussaka; A Georgiou; B Rossiter; S Shrestha; J A Toomey; P V Sivakumar; M Bennett; V Kumar; C G Brooks
Journal:  J Immunol       Date:  1997-01-01       Impact factor: 5.422

6.  NK cells developing in vitro from fetal mouse progenitors express at least one member of the Ly49 family that is acquired in a time-dependent and stochastic manner independently of CD94 and NKG2.

Authors:  Karen P Fraser; Frances Gays; John H Robinson; Katrien van Beneden; Georges Leclercq; Russell E Vance; David H Raulet; Colin G Brooks
Journal:  Eur J Immunol       Date:  2002-03       Impact factor: 5.532

7.  Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow.

Authors:  A W Flake; M G Roncarolo; J M Puck; G Almeida-Porada; M I Evans; M P Johnson; E M Abella; D D Harrison; E D Zanjani
Journal:  N Engl J Med       Date:  1996-12-12       Impact factor: 91.245

8.  Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.

Authors:  Takehito Igarashi; Jason Wynberg; Ramprasad Srinivasan; Brian Becknell; J Phillip McCoy; Yoshiyuki Takahashi; Dante A Suffredini; W Marston Linehan; Michael A Caligiuri; Richard W Childs
Journal:  Blood       Date:  2004-03-11       Impact factor: 22.113

9.  In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI).

Authors:  G S Wengler; A Lanfranchi; T Frusca; R Verardi; A Neva; D Brugnoni; S Giliani; M Fiorini; P Mella; F Guandalini; E Mazzolari; S Pecorelli; L D Notarangelo; F Porta; A G Ugazio
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

10.  KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia.

Authors:  R Willemze; C A Rodrigues; M Labopin; G Sanz; G Michel; G Socié; B Rio; A Sirvent; M Renaud; L Madero; M Mohty; C Ferra; F Garnier; P Loiseau; J Garcia; L Lecchi; G Kögler; Y Beguin; C Navarrete; T Devos; I Ionescu; K Boudjedir; A-L Herr; E Gluckman; V Rocha
Journal:  Leukemia       Date:  2009-01-08       Impact factor: 11.528

View more
  6 in total

1.  Differentiation and functional regulation of human fetal NK cells.

Authors:  Martin A Ivarsson; Liyen Loh; Nicole Marquardt; Eliisa Kekäläinen; Lena Berglin; Niklas K Björkström; Magnus Westgren; Douglas F Nixon; Jakob Michaëlsson
Journal:  J Clin Invest       Date:  2013-08-15       Impact factor: 14.808

2.  Maternal and Fetal Immune Response to in Utero Stem Cell Transplantation.

Authors:  Amir Alhajjat; Aimen Shaaban
Journal:  Curr Stem Cell Rep       Date:  2018-05-03

Review 3.  Immunological considerations in in utero hematopoetic stem cell transplantation (IUHCT).

Authors:  Andrea I Loewendorf; Marie Csete; Alan Flake
Journal:  Front Pharmacol       Date:  2015-01-06       Impact factor: 5.810

Review 4.  NK cell tolerance as the final endorsement of prenatal tolerance after in utero hematopoietic cellular transplantation.

Authors:  Amir M Alhajjat; Amanda E Lee; Beverly S Strong; Aimen F Shaaban
Journal:  Front Pharmacol       Date:  2015-03-18       Impact factor: 5.810

Review 5.  Experimental and clinical progress of in utero hematopoietic cell transplantation therapy for congenital disorders.

Authors:  Chunyu Shi; Lu Pan; Zheng Hu
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

Review 6.  In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application.

Authors:  Graça Almeida-Porada; Anthony Atala; Christopher D Porada
Journal:  Mol Ther Methods Clin Dev       Date:  2016-03-30       Impact factor: 6.698

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.